Our expert eye
Take a look at the experts and opinions that make Kindeva the leading CDMO in the industry.Learn more
St. Paul, MINN — Kindeva Drug Delivery L.P. (Kindeva) announced that Greg Sargen has joined Kindeva’s Board of Directors. The appointment of Mr. Sargen is effective as of April 5, 2021. Mr. Sargen, with over 20 years of experience in the biopharmaceutical and pharmaceutical services industries, will act as a valuable advisor to Kindeva, especially on matters related to finance and business strategy.
Mr. Sargen has held senior leadership and board roles at multiple contract development and manufacturing organizations (CDMOs) and life science companies. He has deep experience in finance, strategy, M&A, and corporate carve-outs in the pharmaceutical services sector. Most recently, he was Executive Vice President of Corporate Development and Strategy and Chief Financial Officer at Cambrex Corporation, where he played a crucial leadership role in growing Cambrex’s business through aggressive internal investment and strategic acquisitions. Mr. Sargen has had senior finance roles at Expanets, Inc. and Fisher Scientific International, Inc. (now Thermo Fisher Scientific, Inc.) and has also held positions at Merck & Co. and Deloitte & Touche LLC.
“Greg’s experience in pharmaceutical services, both as a CFO and a Board Director, is highly relevant to Kindeva,” said Aaron Mann, CEO of Kindeva. “I welcome him to our Board of Directors and am excited to work closely with him as we execute our strategy.”
“I am honored to have the opportunity to serve on this Board and help Aaron and his management team any way I can at this exciting juncture in Kindeva’s history,” said Mr. Sargen. “Kindeva is well-positioned to leverage its considerable strengths in complex drug formulations and delivery methods in the years ahead.”
Mr. Sargen also serves on the Boards of Directors for Avid Bioservices, a CDMO focused on the development and manufacturing of biologics, and Protara Therapeutics, a drug development company. He is a Certified Public Accountant and holds an M.B.A. in Finance from the Wharton School of the University of Pennsylvania and a B.S. in Accounting from Pennsylvania State University.
About Kindeva Drug Delivery
Headquartered in St. Paul, Minnesota, Kindeva Drug Delivery is a leading global contract development and manufacturing organization (CDMO) in the pharmaceutical industry. Kindeva provides unique technologies and quality services to its customers, ranging from formulation and product development to commercial manufacturing. Kindeva focuses on complex drug programs, and its current offering spans inhalation drug delivery, transdermal drug delivery, microstructured transdermal systems (microsystems), and connected drug delivery. Kindeva employs over 1,000 people worldwide. For more information, visit www.kindevadd.com.
Welcome to Kindeva! A new name for a global CDMO with decades of experience.
Kindeva is fueled by the same team of experts who have driven innovation at Riker and 3M for decades. Our culture of passion, creativity and dedication has led to accomplishments that have truly made the world a healthier place.
So bring us your toughest challenges. We’re here to help you solve them—every time.
– Aaron Mann,
CEO of Kindeva Drug Delivery